MedTrace Logo

Personalized Treatment Selection for Metastatic Breast Cancer

NCT00780676 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2020-09-03

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if researchers can use genetic tests to predict who may benefit from treatment with SprycelTM (dasatinib) or selumetinib (AZD6244).

Conditions

Interventions

DRUG

Dasatinib

100 mg tablet by mouth daily

DRUG

AZD6244

75 mg by mouth twice daily.

Sponsors & Collaborators

Principal Investigators

  • Stacy Moulder, MD · UT MD Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00780676 on ClinicalTrials.gov